Evaluate the effect of therapeutic plasma exchange in early intervention and treatment of liver failure

Evaluate the effect of therapeutic plasma exchange in early and mid intervention and treatment of liver failure and neuroimmune system diseases

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037516

Enrollment

Unknown

Registered

2020-08-28

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver failure

Interventions

TPE treatment in early or mid-stage liver failure:therapeutic plasma exchange

Early and mid-stage liver failure treatment by standard drug :standard drug treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Aged >=18 years old, platelet level > 30 x 10^9/L; body temperature =171umol/L or daily increase>=17.1 umol/L), INR 1.5 to 2.6.

Exclusion criteria

Exclusion criteria: (1) Advanced liver failure: clinical symptoms continue to worsen, there is a tendency to severe bleeding (ecchymosis at the injection site, etc.), INR >=2.6, more than one complication and/or more than one extrahepatic organ failure; (2) Patients with liver failure or diffuse intravascular coagulation caused by severe or persistent infection, circulatory failure; (3) Obstructive jaundice or hemolytic jaundice; (4) Those who are severely allergic to blood products used in TPE treatment; (5) Patients with unstable cardiac and cerebral infarction; (6) Pregnant patients; (7) Patients with two or more liver viruses (type A, C, D, E) at the same time.

Design outcomes

Primary

Measure	Time frame
Short-term efficacy;Long-term efficacy;	—

Countries

China

Contacts

Public ContactZhu Xinfang

Fudan University Huashan Hospital

279676540@qq.com+86 13916892629

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026